{"generic":"Poractant Alfa","drugs":["Curosurf","Poractant Alfa"],"mono":{"0":{"id":"jtvrs0","title":"Generic Names","mono":"Poractant Alfa"},"1":{"id":"jtvrs1","title":"Dosing and Indications","sub":{"1":{"id":"jtvrs1b5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy not established for pediatric patients with respiratory failure other than preterm infants<\/li><li><b>Respiratory distress syndrome in the newborn:<\/b> Initial: 2.5 mL\/kg birth weight INTRATRACHEALLY<\/li><li><b>Respiratory distress syndrome in the newborn:<\/b> Repeat doses: Up to 2 repeat doses of 1.25 mL\/kg birth weight may be given at approximately 12-hour intervals in infants who remain intubated and in whom RDS is considered responsible for their persisting or deteriorating respiratory status (MAX recommended total dose is 5 mL\/kg)<\/li><li><b>Respiratory distress syndrome in the newborn; Prophylaxis:<\/b> Study dose, 200 mg\/kg INTRATRACHEALLY within 10 minutes of delivery; a second 200 mg\/kg dose was administered at 6 to 24 hours if more than 60% oxygen was required<\/li><\/ul>"},"3":{"id":"jtvrs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Respiratory distress syndrome in the newborn<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Respiratory distress syndrome in the newborn; Prophylaxis<br\/>"}}},"3":{"id":"jtvrs3","title":"Contraindications\/Warnings","sub":[{"id":"jtvrs3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jtvrs3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- bradycardia has been reported; monitoring required<\/li><li>-- hypotension has been reported; monitoring required<\/li><li>Respiratory:<\/li><li>-- rapid effect on oxygenation and lung compliance may occur; monitoring recommended<\/li><li>-- endotracheal tube blockage has been reported; monitoring required<\/li><li>-- oxygen desaturation has been reported; monitoring required<\/li><\/ul>"},{"id":"jtvrs3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jtvrs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jtvrs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia, Hypotension<\/li><li><b>Respiratory:<\/b>Blocked endotracheal tube, Hypoxia<\/li><\/ul><b>Serious<\/b><br\/><b>Cardiovascular:<\/b>Patent ductus arteriosus (60%)<br\/>"},"6":{"id":"jtvrs6","title":"Drug Name Info","sub":{"0":{"id":"jtvrs6b17","title":"US Trade Names","mono":"Curosurf<br\/>"},"2":{"id":"jtvrs6b19","title":"Class","mono":"Lung Surfactant<br\/>"},"3":{"id":"jtvrs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jtvrs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jtvrs7","title":"Mechanism Of Action","mono":"<ul><li>Intratracheal-Local: Poractant alfa is a natural porcine lung extract containing phospholipids and two hydrophobic, low-molecular-weight surfactant-associated proteins, SP-B and SP-C.<\/li><li> When poractant alfa is used as a replacement for deficient endogenous lung surfactant, it is effective in lowering surface tension on alveolar surfaces during respiration and stabilizing the alveoli against collapse at resting transpulmonary pressures. Therefore, poractant alfa reduces mortality and pneumothoraces associated with RDS.<\/li><\/ul>"},"9":{"id":"jtvrs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For intratracheal use only<br\/><\/li><li><b>Intratracheal<\/b><br\/><ul><li>Slowly warm vial to room temperature before administration<\/li><li>Discard if suspension discolored (other than white to creamy white)<\/li><li>Immediately before administration, change the infant's ventilator settings to a rate of 40 to 60 breaths\/minute, inspiratory time 0.5 second, and supplemental oxygen sufficient to maintain oxygen saturation at greater than 92%<\/li><li>Keep infant in neutral position; briefly disconnect the endotracheal tube from the ventilator and instill the first aliquot (1.25 mL\/kg) through a precut (8 cm in length) 5 French end-hole catheter<\/li><li>Alternatively, may administer solution through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation<\/li><li>After administration, disconnect catheter from the endotracheal tube and manually ventilate with 100% oxygen at 40 to 60 breaths\/min for 1 min<\/li><li>When the infant is stable, reposition the infant such that the other side is dependent and administer the remaining aliquot using the same procedures<\/li><li>After instillation of the second aliquot, remove the catheter without flushing<\/li><li>Do not suction airway for 1 hour after administration unless clinically necessary<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jtvrs10","title":"Monitoring","mono":"<ul><li>proper placement and patency of endotracheal tube: prior to administration<\/li><li>improvements in symptoms of respiratory distress syndrome may indicate efficacy<\/li><li>acute changes in oxygenation and lung compliance; frequently<\/li><li>adverse events during administration, including bradycardia, hypotension, and endotracheal tube blockage<\/li><\/ul>"},"11":{"id":"jtvrs11","title":"How Supplied","mono":"<b>Curosurf<\/b><br\/>Intratracheal Suspension: 80 MG\/ML<br\/>"}}}